



## **ASX ANNOUNCEMENT**

**21 January 2015**

### **Acceptance Date of 180-Day EMA Response Deferred by 1 Month**

Biomedical company, Tissue Therapies Limited (**ASX: TIS**) was informed before market open today by the Notified Body (BSI) that the EMA has deferred acceptance of the Company's response to the 180-day review questions for the granting of CE Mark by one month.

An opinion from the EMA Review Committee is now expected on 26 March instead of 26 February 2015

Once the EMA Committee has arrived at an opinion, this will be conveyed to BSI and then BSI will inform Tissue Therapies of the opinion.

## **VitroGro<sup>®</sup> ECM: a healing promoter for chronic wounds**

- VitroGro<sup>®</sup> ECM is a synthetic matrix protein that is used to promote healing in chronic wounds.
- Chronic wounds are a burden to both the patient and healthcare systems and have been described as “major and snowballing threat to public health and the economy” and therefore require the attention of advanced therapies to address the problem <sup>[1]</sup>.
- Chronic wounds are those in which the normal healing process becomes stalled resulting in prolonged inflammation. Typically these wounds do not respond well to standard therapies because the growth of new skin to cover the wound is compromised.
- The growth of new skin is an anchorage dependent process that requires a protein matrix to which skin cells can attach. The prolonged inflammation in chronic wounds damages the protein matrix required for cell attachment and inhibits its restoration delaying or halting healing. Healing can be reinstated in chronic wounds by replacing this damaged matrix with a substitute that promotes healing.
- VitroGro<sup>®</sup> ECM contains a portion of the vitronectin protein that is specifically active in adhering to other proteins in the wound bed and providing sites for the attachment of skin cells. VitroGro<sup>®</sup> ECM also contains the growth factor IGF-I that helps support the growth (migration and proliferation) of attached cells. This design targets the stages of normal healing at which chronic wounds stall, promoting healing by replacing the damaged protein matrix of chronic wounds, providing sites for skin cell attachment, which restores the anchorage dependent growth of skin cells that is required for healing.

[1] Chandon K Sen *et al.* Human skin wounds: A major and snowballing threat to public health and the economy. Wound Repair and Regeneration 2009.

### **About Tissue Therapies Limited**

Tissue Therapies Limited is a biomedical technology company that is developing significantly more effective treatments for acute and chronic wound healing applications, including chronic skin ulcers and burns.

Tissue Therapies Limited is commercialising VitroGro<sup>®</sup> ECM, a technology created by cell biology, tissue engineering and protein engineering experts at the Institute of Health and Biomedical Innovation at the Queensland University of Technology. The company is also developing treatments for psoriasis, scar prevention and various cancers including those of the breast, colon and prostate. Tissue Therapies Limited's shares are traded on the Australian, Berlin and Frankfurt stock exchanges.

More information: [www.tissuetherapies.com](http://www.tissuetherapies.com)